BUSINESS
BioWa Out-Licenses Kyowa Hakko Kirin’s Technologies and Serves as Its “In-Licensing Window”; “Naked” Mabs to Remain Dominant until 2002
Masamichi Koike, Ph.D., director of the Development Planning Department, Development Division of Kyowa Hakko Kirin Co., Ltd. (KHK) spoke about the present and future of therapeutic antibodies and looked back over the first 10 years of BioWa, Inc., a US…
To read the full story
BUSINESS
- Bayer Detects Nitrosamine in Contrast Agent, Restricts Shipments
April 27, 2026
- Chugai to Launch 3 Global PIIIs of Bispecific Antibody NXT007 in 2026
April 27, 2026
- Astellas Bags US$75 Million from MSN after Myrbetriq Patent Settlement
April 27, 2026
- Kura, Kyowa Kirin Start Japan PII Trial of Ziftomenib for AML Filing
April 27, 2026
- Pharma Earnings Season Kicks Off; Off-Year Impact, Overseas Trends in Focus
April 24, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





